Print
Print
Advertisement
Cecilia BrownMyelodysplastic Syndromes | February 7, 2023
Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms.
Read More
Laurie Sehn, MD, MPHAggressive B-Cell Lymphoma | February 7, 2023
Given the multitude of novel therapies recently approved, clinicians must consider how to best sequence the options.
Leah LawrenceAggressive B-Cell Lymphoma | February 7, 2023
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Thomas Martin, MDMyeloma | February 7, 2023
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Cecilia BrownAcute Myeloid Leukemia | February 7, 2023
Combining proteomic data with genetic risk-stratification data may help tailor therapy for pediatric AML.
Leah SherwoodAggressive B-Cell Lymphoma | February 7, 2023
Glofitamab is an investigational CD20×CD3 T-cell-engaging bispecific antibody.
Advertisement
Leah SherwoodAcute Myeloid Leukemia | February 7, 2023
Maintenance therapy strategies for AML have been investigated for decades, including single agents and combinations.
Leah SherwoodPrint | February 5, 2023
Chadi Nabhan, MD, MBA, FACP, hosts The HemOnc Pulse, a podcast from Blood Cancers Today and SOHO.
Cecilia BrownMyeloma | January 25, 2023
The FDA received a Biologics License Application for the use of talquetamab in patients with R/R multiple myeloma.
Leah SherwoodChronic Lymphocytic Leukemia | January 19, 2023
The U.S. Food and Drug Administration (FDA) has approved zanubrutinib for the treatment of CLL and SLL.
Leah SherwoodChronic Lymphocytic Leukemia | January 13, 2023
BCL2 inhibitors (eg, venetoclax) have clinical benefits for patients with CLL, but overcoming resistance remains a challenge.
Leah SherwoodPrint | January 13, 2023
Elranatamab was granted Breakthrough Therapy Designation by the U.S. FDA for relapsed/refractory multiple myeloma.
Cecilia BrownMantle Cell Lymphoma | January 13, 2023
Jonathon Cohen, MD, discusses how he came to focus on lymphoma, as well as current research, pressing questions, and more.
Cecilia BrownChronic Lymphocytic Leukemia | January 13, 2023
Moxetumomab pasudotox will be discontinued from the market in the US in July 2023.
Jennifer R. Brown, MD, PhDPrint | January 13, 2023
Jennifer R. Brown, MD, PhD, and Anthony Mato, MD, MSCE, debate combinations versus sequencing approaches in CLL.
Leah SherwoodPrint | January 13, 2023
Orelabrutinib has been approved by the Health Sciences Authority of Singapore for the treatment of adults with MCL.
Leah SherwoodPrint | January 13, 2023
The European Commission has approved zanubrutinib for the treatment of adults with chronic lymphocytic leukemia.
Leah SherwoodPrint | January 13, 2023
The U.S. FDA has accepted for review and filed the New Drug Application for motixafortide.
Cecilia BrownPrint | January 13, 2023
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Cecilia BrownPrint | January 13, 2023
Lenalidomide plus rituximab is “an acceptable chemotherapy-free alternative” to rituximab plus chemo in patients with FL.
Advertisement
Advertisement
Editorial Board